Department of Pediatrics, Wake Forest School of Medicine, Winston-Salem, North Carolina.
Department of Microbiology, KS Hegde Medical Academy, Nitte (Deemed to be University), Deralakatte, Mangalore, India.
Am J Trop Med Hyg. 2021 Aug 9;105(4):966-973. doi: 10.4269/ajtmh.20-1650.
Cervical cancer is the second leading cause of cancer and one of the leading causes of cancer-related death in women in India. Human papillomavirus (HPV) vaccine uptake in India is low due to cost, low awareness of HPV, social stigma, and other factors. We assessed the awareness, attitudes, and beliefs regarding HPV and HPV vaccination and explored the barriers and challenges to HPV vaccine intent among women in Mangalore, India. An exploratory study was conducted using two focus group discussions (FGDs) and six in-depth one-on-one interviews. FGD-1 comprised nine women aged 18 to 26 years, and FGD-2 comprised seven women aged 27 to 45 years. The FGDs were recorded, transcribed, and analyzed using thematic content analysis. Themes identified were limited knowledge of HPV and vaccine, stigma associated with receiving HPV vaccine, vaccine safety concerns, and cost as a barrier to receiving vaccine. Participants expressed desire for physician and government recommendation of the HPV vaccine to validate vaccine intent. Contrasting themes between the two FGDs include support for vaccination at a younger age and lower perception of stigma and judgment in the 18- to 26-year-old group; however, participants in the 27- to 45-year-old group support vaccination at an older age and endorse greater fear of stigma and judgment associated with obtaining vaccination. Education regarding HPV-associated diseases and the HPV vaccine for the general public, physicians, and government officials in conjunction with lowering vaccine cost, improving vaccine access, and encouraging strong physician recommendations are key strategies to scale up HPV vaccine implementation in India.
在印度,宫颈癌是导致女性癌症的第二大原因,也是癌症相关死亡的主要原因之一。由于费用、对 HPV 的认识低、社会耻辱感和其他因素,印度的人乳头瘤病毒 (HPV) 疫苗接种率较低。我们评估了印度芒格洛尔女性对 HPV 和 HPV 疫苗的认识、态度和信念,并探讨了 HPV 疫苗接种意愿的障碍和挑战。使用两项焦点小组讨论(FGD)和六项深入的一对一访谈进行了探索性研究。FGD-1 由 9 名年龄在 18 至 26 岁的女性组成,FGD-2 由 7 名年龄在 27 至 45 岁的女性组成。对 FGD 进行了记录、转录和分析,采用主题内容分析。确定的主题包括对 HPV 和疫苗的了解有限、与接种 HPV 疫苗相关的耻辱感、疫苗安全性担忧以及费用是接种疫苗的障碍。参与者表示希望医生和政府推荐 HPV 疫苗,以验证接种疫苗的意愿。两个 FGD 之间的对比主题包括在 18 至 26 岁年龄组中支持在更年轻时接种疫苗和对耻辱感和判断的看法较低;然而,在 27 至 45 岁年龄组中,参与者支持在较年长时接种疫苗,并支持与获得疫苗接种相关的更大的耻辱感和判断恐惧。为公众、医生和政府官员提供有关 HPV 相关疾病和 HPV 疫苗的教育,以及降低疫苗成本、改善疫苗获取和鼓励医生强烈推荐,是在印度扩大 HPV 疫苗实施的关键策略。